Lundbeck and Otsuka Pharmaceutical announce positive results showing reduced agitation in patients with Alzheimer’s dementia treated with brexpiprazole
· Results from a phase III clinical study for treatment of agitation in patients with Alzheimer’s dementia showed that patients treated with brexpiprazole had a statistically significantly greater reduction in agitation compared to placebo · Agitation is a very prevalent clinical manifestation in Alzheimer’s dementia and one of the most complex and stressful aspects of care in patients affected by the disease. It is associated with greater caregiver burden, earlier nursing home placement, increased morbidity and mortality and a substantial economic burden. · Currently there are no FDA